Cargando…

Icaritin Inhibits JAK/STAT3 Signaling and Growth of Renal Cell Carcinoma

Signal transducer and activator of transcription-3 (STAT3) is critical for cancer progression by regulating tumor cell survival, proliferation, and angiogenesis. Herein, we investigated the regulation of STAT3 activation and the therapeutic effects of Icaritin, a prenyl flavonoid derivative from Epi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shasha, Priceman, Saul J., Xin, Hong, Zhang, Wang, Deng, Jiehui, Liu, Yong, Huang, Jiabin, Zhu, Wenshan, Chen, Mingjie, Hu, Wei, Deng, Xiaomin, Zhang, Jian, Yu, Hua, He, Guangyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3855768/ https://www.ncbi.nlm.nih.gov/pubmed/24324713 http://dx.doi.org/10.1371/journal.pone.0081657

Ejemplares similares

Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3
por: Zhu, Shicong, et al.
Publicado: (2015)

Icaritin Reduces Oral Squamous Cell Carcinoma Progression via the Inhibition of STAT3 Signaling
por: Yang, Jian-Guang, et al.
Publicado: (2017)

A novel anti-cancer agent Icaritin suppresses hepatocellular carcinoma initiation and malignant growth through the IL-6/Jak2/Stat3 pathway
por: Zhao, Hong, et al.
Publicado: (2015)

Icaritin inhibits decidualization of endometrial stromal cells
por: Le, Aiwen, et al.
Publicado: (2017)

Icaritin Shows Potent Anti-Leukemia Activity on Chronic Myeloid Leukemia In Vitro and In Vivo by Regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT Signalings
por: Zhu, Jian feng, et al.
Publicado: (2011)

Icaritin-Induced FAM99A Affects GLUT1-Mediated Glycolysis via Regulating the JAK2/STAT3 Pathway in Hepatocellular Carcinoma
por: Zheng, Xia, et al.
Publicado: (2021)

Icaritin inhibits CDK2 expression and activity to interfere with tumor progression
por: Zhang, Chao, et al.
Publicado: (2022)

Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
por: Harel, Sivan, et al.
Publicado: (2015)

A comparative study on the in vitro and in vivo antitumor efficacy of icaritin and hydrous icaritin nanorods
por: Li, Haowen, et al.
Publicado: (2020)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

Dexmedetomidine protects against renal ischemia and reperfusion injury by inhibiting the JAK/STAT signaling activation
por: Si, Yanna, et al.
Publicado: (2013)

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition
por: McInnes, Iain B, et al.
Publicado: (2021)

ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway
por: Shen, Yu-Li, et al.
Publicado: (2020)

AMPK-autophagy inhibition sensitizes icaritin-induced anti-colorectal cancer cell activity
por: Zhou, Chunxian, et al.
Publicado: (2017)

Pharmacokinetics and metabolism of icaritin in rats by UPLC‐MS/MS
por: Huang, Zhen‐Wu, et al.
Publicado: (2019)

Natural product-derived icaritin exerts anti-glioblastoma effects by positively modulating estrogen receptor β
por: Li, Xiaowen, et al.
Publicado: (2020)

Leptin-Induced JAK/STAT Signaling and Cancer Growth
por: Mullen, McKay, et al.
Publicado: (2016)

Icaritin inhibits PD‐L1 expression by Targeting Protein IκB Kinase α
por: Mo, Dongliang, et al.
Publicado: (2021)

Pharmacological inhibition of demethylzeylasteral on JAK-STAT signaling ameliorates vitiligo
por: Chang, Yuqian, et al.
Publicado: (2023)

Protein Inhibitor of Activated STAT (PIAS) Negatively Regulates the JAK/STAT Pathway by Inhibiting STAT Phosphorylation and Translocation
por: Niu, Guo-Juan, et al.
Publicado: (2018)

Icaritin: A Novel Natural Candidate for Hematological Malignancies Therapy
por: Yang, Xiao-Jing, et al.
Publicado: (2019)

Corrigendum: ErHuang Formula Improves Renal Fibrosis in Diabetic Nephropathy Rats by Inhibiting CXCL6/JAK/STAT3 Signaling Pathway
por: Shen, Yu-Li, et al.
Publicado: (2021)

JAKs and STATs in chemoresistance
por: Costa-Pereira, Ana P
Publicado: (2010)

JAK-STAT and feeding
por: Ladyman, Sharon R., et al.
Publicado: (2013)

The molecular basis of JAK/STAT inhibition by SOCS1
por: Liau, Nicholas P. D., et al.
Publicado: (2018)

Investigating the effect of Icaritin on hepatocellular carcinoma based on network pharmacology
por: Xue, Zhong, et al.
Publicado: (2023)

Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway
por: Li, Hongbo, et al.
Publicado: (2018)

Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma
por: Li, Hui, et al.
Publicado: (2021)

PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway
por: Lei, Zhong, et al.
Publicado: (2018)

Simvastatin Inhibits Renal Cancer Cell Growth and Metastasis via AKT/mTOR, ERK and JAK2/STAT3 Pathway
por: Fang, Zhiqing, et al.
Publicado: (2013)

CXCL6 Promotes Renal Interstitial Fibrosis in Diabetic Nephropathy by Activating JAK/STAT3 Signaling Pathway
por: Sun, Meng-Yao, et al.
Publicado: (2019)

Icaritin Synergistically Enhances the Radiosensitivity of 4T1 Breast Cancer Cells
por: Hong, Jinsheng, et al.
Publicado: (2013)

Icaritin ameliorates RANKL-mediated osteoclastogenesis and ovariectomy-induced osteoporosis
por: Huang, Jun-ming, et al.
Publicado: (2023)

Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma
por: Yang, Shuqun, et al.
Publicado: (2015)

Inhibition of the JAK2/STAT3 Pathway Reduces Gastric Cancer Growth In Vitro and In Vivo
por: Judd, Louise M., et al.
Publicado: (2014)

Capsazepine inhibits JAK/STAT3 signaling, tumor growth, and cell survival in prostate cancer
por: Lee, Jong Hyun, et al.
Publicado: (2016)

VSIG4 Silencing Inhibits Glioblastoma Growth by Regulating the JAK2/STAT3 Pathway
por: Zheng, Congying, et al.
Publicado: (2023)

Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway
por: Xu, Peng, et al.
Publicado: (2022)

Antiosteoporosis Effects, Pharmacokinetics, and Drug Delivery Systems of Icaritin: Advances and Prospects
por: Gao, Lifang, et al.
Publicado: (2022)

Icaritin, a novel FASN inhibitor, exerts anti-melanoma activities through IGF-1R/STAT3 signaling
por: Wu, Jinfeng, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8jm1u0l5kadtkabtt29qcbregh